Fasenra approved in China for the treatment of severe eosinophilic asthma
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control.AstraZeneca’s Fasenra (benralizumab) has been approved in China by the country’s National Medical Products Association (NMPA) for the maintenance treatment of patients 12 years of age and older with severe eosinophilic asthma (SEA).[1] The approval is based on results from the MIRACLE Phase III trial, which was conducted in China, South Korea and the Philippines.[2] In the trial, Fasenra achieved a statistically